Home » Topics » BioWorld Science

BioWorld Science
RSS

HiberCell begins phase Ia study of PERK inhibitor HC-5404-FU in metastatic solid tumors

June 11, 2021

Phase II proof-of-concept study of VX-864 in AATD meets primary endpoint

June 11, 2021

Circulating markers of collagen turnover tied to disease severity in ADPKD

June 11, 2021

Myelin renewal reverses AD cognitive dysfunction in mice

June 11, 2021

Phase I data for seclidemstat in R/R Ewing sarcoma

June 11, 2021

Iptacopan safely and effectively stabilizes eGFR in patients with C3 glomerulopathy

June 11, 2021

Vor Biopharma and Abound Bio partner to develop multi-targeted CAR-Ts

June 11, 2021

Berdazimer sodium shows promising efficacy in preclinical SARS-CoV-2 transmission model

June 11, 2021

Sovateltide slows down the progression of Alzheimer's disease in phase II study

June 11, 2021

First patient dosed in phase I study of CID-103 in multiple myeloma

June 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.